Published in Gastroenterology on March 01, 1989
Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med (1995) 6.89
Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut (2000) 4.32
Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest (2004) 3.90
Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med (1998) 3.50
Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology (2008) 2.99
The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest (2004) 2.52
Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut (2001) 2.46
Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS One (2009) 2.35
Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest (1996) 2.31
Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med (1996) 2.30
NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis (2010) 1.84
Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol (2002) 1.79
A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol (2009) 1.70
Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses. J Exp Med (1999) 1.69
Enhanced excitability of myenteric AH neurones in the inflamed guinea-pig distal colon. J Physiol (2003) 1.65
Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci U S A (2008) 1.55
Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut (1994) 1.47
Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol (2007) 1.45
Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest (1997) 1.44
Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model. Appl Environ Microbiol (2006) 1.42
Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol (2013) 1.41
Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci (2012) 1.40
Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut (1996) 1.39
Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol (2003) 1.38
Interleukin 10 gene transfer prevents experimental colitis in rats. Gut (2000) 1.38
The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype. J Cancer Res Clin Oncol (2006) 1.36
Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol (2011) 1.35
Role of inducible nitric oxide synthase in trinitrobenzene sulphonic acid induced colitis in mice. Gut (1999) 1.35
Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut (1990) 1.34
The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br J Pharmacol (2006) 1.33
A paradoxical reduction in susceptibility to colonic injury upon targeted transgenic ablation of goblet cells. J Clin Invest (1999) 1.31
Visceral and somatic hypersensitivity in a subset of rats following TNBS-induced colitis. Pain (2007) 1.30
Noninvasive ultrasound elasticity imaging (UEI) of Crohn's disease: animal model. Ultrasound Med Biol (2008) 1.29
Transforming growth factor-beta mediates intestinal healing and susceptibility to injury in vitro and in vivo through epithelial cells. Am J Pathol (2003) 1.29
Butyrate enema therapy stimulates mucosal repair in experimental colitis in the rat. Gut (1996) 1.28
Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci U S A (2005) 1.25
Role of interleukin 15 in colitis induced by dextran sulphate sodium in mice. Gut (2005) 1.23
Changes of colonic mucosal microcirculation and histology in two colitis models: an experimental study using intravital microscopy and a new histological scoring system. Dig Dis Sci (2001) 1.21
Visceral pain: the neurophysiological mechanism. Handb Exp Pharmacol (2009) 1.21
Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras. Biochem Pharmacol (2012) 1.19
Reduced oxidative and nitrosative damage in murine experimental colitis in the absence of inducible nitric oxide synthase. Gut (1999) 1.19
Essential role for mast cell tryptase in acute experimental colitis. Proc Natl Acad Sci U S A (2010) 1.17
Selective induction of integrin beta1 by hypoxia-inducible factor: implications for wound healing. FASEB J (2008) 1.17
Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models, and neuroimaging. Neuroimage (2009) 1.17
Mechanisms involved in alleviation of intestinal inflammation by bifidobacterium breve soluble factors. PLoS One (2009) 1.15
A critical role for alveolar macrophages in elicitation of pulmonary immune fibrosis. Immunology (2000) 1.15
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
A review on chemical-induced inflammatory bowel disease models in rodents. Korean J Physiol Pharmacol (2014) 1.15
Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. J Gastroenterol (2010) 1.14
Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. Clin Diagn Lab Immunol (2003) 1.14
Specific regulation of T helper cell 1-mediated murine colitis by CEACAM1. J Exp Med (2004) 1.14
Short-chain fructooligosaccharides, in spite of being fermented in the upper part of the large intestine, have anti-inflammatory activity in the TNBS model of colitis. Eur J Nutr (2006) 1.14
Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-alpha, NF-kappaBp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm (2006) 1.14
Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Gut (1998) 1.14
Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut (2000) 1.13
Anti-inflammatory effect of diosmectite in hapten-induced colitis in the rat. Br J Pharmacol (2004) 1.13
Effects of extract and essential oil of Rosmarinus officinalis L. on TNBS-induced colitis in rats. Res Pharm Sci (2011) 1.12
Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis. World J Gastroenterol (2005) 1.12
Ultrasound elasticity imaging for detecting intestinal fibrosis and inflammation in rats and humans with Crohn's disease. Gastroenterology (2011) 1.12
Non-lymphoid and lymphoid cells in acute, chronic and relapsing experimental colitis. Clin Exp Immunol (1995) 1.11
Up-regulation of calcitonin gene-related peptide and receptor tyrosine kinase TrkB in rat bladder afferent neurons following TNBS colitis. Exp Neurol (2007) 1.09
Anti-CD11b/CD18 antibodies reduce inflammation in acute colitis in rats. Clin Exp Immunol (1995) 1.09
Development of colonic neoplasia in p53 deficient mice with experimental colitis induced by dextran sulphate sodium. Gut (2004) 1.08
Effects of L-carnitine on oxidant/antioxidant status in acetic acid-induced colitis. Dig Dis Sci (2006) 1.07
Intestinal inflammation in TNBS sensitized rats as a model of chronic inflammatory bowel disease. Mediators Inflamm (1992) 1.07
Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut (1999) 1.07
Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol (2006) 1.06
Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut (2003) 1.06
Reversal of visceral and somatic hypersensitivity in a subset of hypersensitive rats by intracolonic lidocaine. Pain (2008) 1.05
Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis. Eur J Nutr (2009) 1.04
Ketotifen effectively prevents mucosal damage in experimental colitis. Gut (1992) 1.03
Experimental ulcerative colitis impairs antioxidant defense system in rat intestine. Dig Dis Sci (2000) 1.02
Tumour necrosis factor alpha and nuclear factor kappaB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide. Gut (2003) 1.02
Protective effect of angelica sinensis polysaccharide on experimental immunological colon injury in rats. World J Gastroenterol (2003) 1.01
Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis. World J Gastroenterol (2005) 1.00
Do vitamin E and selenium have beneficial effects on trinitrobenzenesulfonic acid-induced experimental colitis. Dig Dis Sci (2004) 1.00
Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats. Postgrad Med J (2006) 1.00
Melatonin reduces inflammatory injury through inhibiting NF-kappaB activation in rats with colitis. Mediators Inflamm (2005) 0.99
Lactobacillus fermentum, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis. Int J Colorectal Dis (2005) 0.99
Calpain inhibitor I reduces colon injury caused by dinitrobenzene sulphonic acid in the rat. Gut (2001) 0.99
Selective up-regulation of NMDA-NR1 receptor expression in myenteric plexus after TNBS induced colitis in rats. Mol Pain (2006) 0.98
Surface hydrophobicity of the rat colonic mucosa is a defensive barrier against macromolecules and toxins. Gut (2000) 0.98
Involvement of MAPK/NF-κB signaling in the activation of the cholinergic anti-inflammatory pathway in experimental colitis by chronic vagus nerve stimulation. PLoS One (2013) 0.98
A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br J Pharmacol (2009) 0.97
Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitronbenzene sulphonic acid. Gut (2005) 0.97
SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis. Dig Dis Sci (1999) 0.97
Dietary monounsaturated n-3 and n-6 long-chain polyunsaturated fatty acids affect cellular antioxidant defense system in rats with experimental ulcerative colitis induced by trinitrobenzene sulfonic acid. Dig Dis Sci (1998) 0.97
Colitis and colonic mucosal barrier dysfunction. Gut (1995) 0.96
Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol (2003) 0.96
Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig Dis Sci (1997) 0.96
Endogenous IGF-I and alpha v beta3 integrin ligands regulate increased smooth muscle growth in TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol (2009) 0.95
Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease. Inflammopharmacology (2010) 0.95
Daikenchuto (TU-100) ameliorates colon microvascular dysfunction via endogenous adrenomedullin in Crohn's disease rat model. J Gastroenterol (2011) 0.95
Preventive and therapeutic euphol treatment attenuates experimental colitis in mice. PLoS One (2011) 0.95
Nuclear myosin II regulates the assembly of preinitiation complex for ICAM-1 gene transcription. Gastroenterology (2009) 0.95
Protection from experimental colitis by theaflavin-3,3'-digallate correlates with inhibition of IKK and NF-kappaB activation. Br J Pharmacol (2006) 0.95
CD4+ T cells from 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis rodents migrate to the recipient's colon upon transfer; down-regulation by CD8+ T cells. Clin Exp Immunol (1998) 0.94
Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol (2000) 4.12
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med (2000) 3.71
Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology (1989) 3.24
Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway. Nat Med (2001) 3.17
Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol (1999) 2.70
Sucrose: a novel permeability marker for gastroduodenal disease. Gastroenterology (1993) 2.46
Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest (1996) 2.31
A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology (1995) 2.30
Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci (2001) 2.06
Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci U S A (2001) 1.84
Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br J Pharmacol (1999) 1.83
Suppression of fever at near term is associated with reduced COX-2 protein expression in rat hypothalamus. Am J Physiol Regul Integr Comp Physiol (2002) 1.80
Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature (1986) 1.73
Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology (1997) 1.69
Proteinase-activated receptor 2 (PAR2)-activating peptides: identification of a receptor distinct from PAR2 that regulates intestinal transport. Proc Natl Acad Sci U S A (1998) 1.61
Representation of three-dimensional objects by the rat perirhinal cortex. Hippocampus (2012) 1.60
Prevalence of IgA-antiendomysial antibody in asymptomatic low bone mineral density. Am J Gastroenterol (2001) 1.54
Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am J Physiol (1990) 1.46
Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol (2007) 1.45
Nitric oxide synthesis inhibition increases epithelial permeability via mast cells. Am J Physiol (1994) 1.44
Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A (2001) 1.39
Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol (1995) 1.36
The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol (2001) 1.32
A paradoxical reduction in susceptibility to colonic injury upon targeted transgenic ablation of goblet cells. J Clin Invest (1999) 1.31
Disruption of colonic electrolyte transport in experimental colitis. Am J Physiol (1995) 1.31
Nitric Oxide. V. therapeutic potential of nitric oxide donors and inhibitors. Am J Physiol (1999) 1.27
Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease. Agents Actions (1988) 1.27
NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther (1997) 1.26
Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am J Physiol Gastrointest Liver Physiol (2000) 1.25
Evidence for platelet-activating factor as a mediator of endotoxin-induced gastrointestinal damage in the rat. Effects of three platelet-activating factor antagonists. Gastroenterology (1987) 1.24
Persistent epithelial dysfunction and bacterial translocation after resolution of intestinal inflammation. Am J Physiol Gastrointest Liver Physiol (2001) 1.23
Prolonged colonic epithelial hyporesponsiveness after colitis: role of inducible nitric oxide synthase. Am J Physiol (1999) 1.21
A simple, non-invasive marker of gastric damage: sucrose permeability. Lancet (1994) 1.20
Effects of chemical sympathectomy and sensory nerve ablation on experimental colitis in the rat. Am J Physiol (1997) 1.19
Endothelium-derived relaxing factor (nitric oxide) has protective actions in the stomach. Life Sci (1989) 1.19
Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br J Pharmacol (2001) 1.18
The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br J Pharmacol (1988) 1.18
Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome. Gut (2001) 1.17
Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol (1994) 1.16
Role of mucus in the repair of gastric epithelial damage in the rat. Inhibition of epithelial recovery by mucolytic agents. Gastroenterology (1986) 1.16
Proteinase-activated receptor-2-mediated matrix metalloproteinase-9 release from airway epithelial cells. J Allergy Clin Immunol (2000) 1.15
NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br J Pharmacol (2000) 1.14
Aquaporin expression is downregulated in a murine model of colitis and in patients with ulcerative colitis, Crohn's disease and infectious colitis. Cell Tissue Res (2004) 1.14
Role of prostanoids in the protective actions of BW755C on the gastric mucosa. Eur J Pharmacol (1985) 1.14
Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol (1996) 1.14
Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci (1998) 1.11
Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1). Br J Pharmacol (1999) 1.11
Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc Natl Acad Sci U S A (2000) 1.11
Impairment of host-versus-graft reaction in pregnant mice. II. Selective suppression of cytotoxic T-cell generation correlates with soluble suppressor activity and with successful allogeneic pregnancy. Cell Immunol (1980) 1.11
The association of coeliac disease and microscopic colitis: a large population-based study. Aliment Pharmacol Ther (2011) 1.11
Prevention of endotoxin-induced gastrointestinal damage by CV-3988, an antagonist of platelet-activating factor. Eur J Pharmacol (1986) 1.10
Picomole doses of platelet-activating factor predispose the gastric mucosa to damage by topical irritants. Prostaglandins (1986) 1.10
Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol (2000) 1.09
Role of oxygen-derived free radicals in indomethacin-induced gastric injury. Am J Physiol (1991) 1.09
Spontaneously developing chronic colitis in IL-10/iNOS double-deficient mice. Am J Physiol Gastrointest Liver Physiol (2000) 1.07
A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol (2003) 1.07
Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. Am J Physiol Gastrointest Liver Physiol (2000) 1.06
Ontogeny of B-lymphocyte function. III. In vivo and in vitro studies on the ease of tolerance induction in B lymphocytes from fetal, neonatal, and adult mice. J Exp Med (1977) 1.06
Aspirin causes rapid up-regulation of cyclo-oxygenase-2 expression in the stomach of rats. Aliment Pharmacol Ther (1997) 1.06
Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut (2003) 1.06
Induction of cyclooxygenase 1 and 2 in the rat stomach during endotoxemia: role in resistance to damage. Gastroenterology (1997) 1.06
Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid. J Pharmacol Toxicol Methods (1995) 1.06
The roles of ethanol and of acid in the production of gastric mucosal erosions in rats. Virchows Arch B Cell Pathol Incl Mol Pathol (1981) 1.05
Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. Br J Pharmacol (2001) 1.05
Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci (1998) 1.05
Lack of age-associated immune dysfunction in mucosal-associated lymph nodes. J Immunol (1981) 1.04
Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor. Br J Pharmacol (2000) 1.03
Bacteria rapidly colonize and modulate healing of gastric ulcers in rats. Am J Physiol (1998) 1.03
Prostaglandins inhibit inflammatory mediator release from rat mast cells. Gastroenterology (1993) 1.03
Profile of gastrointestinal damage induced by platelet-activating factor. Prostaglandins (1986) 1.03
Prostaglandin protection of rat colonic mucosa from damage induced by ethanol. Dig Dis Sci (1985) 1.02
Protease-activated receptor-1 stimulates Ca(2+)-dependent Cl(-) secretion in human intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol (2001) 1.02
Reduction by cytoprotective agents of ethanol-induced damage to the rat gastric mucosa: a correlated morphological and physiological study. Can J Physiol Pharmacol (1982) 1.01
Increased intestinal formation of Paf in endotoxin-induced damage in the rat. Br J Pharmacol (1987) 1.00
Potentiation of tumor necrosis factor-alpha-mediated cytotoxicity of mast cells by their production of nitric oxide. J Immunol (1991) 0.99
Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. Gastroenterology (1995) 0.99
Loss of immune competence with age may be due to auto-anti-idiotypic antibody regulation. Nature (1980) 0.98
Ontogeny of B-lymphocyte function. V. Thymus cell involvement in the functional maturation of B-lymphocytes from fetal mice transferred into adult irradiated hosts. J Exp Med (1978) 0.97
A functional model for extracellular gastric mucus in the rat. Virchows Arch B Cell Pathol Incl Mol Pathol (1984) 0.97
Modulation of cellular phospholipid fatty acids and leukotriene B4 synthesis in the human intestinal cell (CaCo-2). Gut (1992) 0.96
The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms. Am J Gastroenterol (1998) 0.96
Prostaglandin biosynthesis by gastric mucosa. II. Studies in man. Clin Biochem (1984) 0.95
Isotretinoin-associated proctosigmoiditis. Gastroenterology (1987) 0.95
Effects of inhibitors of arachidonic acid metabolism on Paf-induced gastric mucosal necrosis and haemoconcentration. Br J Pharmacol (1986) 0.95
Age-related strain differences in the development of auto-anti-idiotypic antibody regulation in the splenic and mucosal-associated lymphoid systems. Gerontology (1985) 0.95
Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative Colitis. Inflamm Bowel Dis (1997) 0.95
Aging, idiotype repertoire shifts, and compartmentalization of the mucosal-associated lymphoid system. Adv Immunol (1984) 0.93
Modulation of rat mast cell reactivity by IL-1 beta. Divergent effects on nitric oxide and platelet-activating factor release. J Immunol (1993) 0.93
Enhanced suppressor cell activity as a mechanism of immunosuppression by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc Soc Exp Biol Med (1981) 0.93
Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. Am J Physiol Heart Circ Physiol (2000) 0.92
Cytokines in inflammatory bowel disease. Mediators Inflamm (1997) 0.91
Alendronate induces gastric injury and delays ulcer healing in rodents. Life Sci (1998) 0.91
Prostaglandin biosynthesis by gastric mucosa. I. Studies in rat. Clin Biochem (1984) 0.91
The risk of gastrointestinal malignancies in cystic fibrosis: case report of a patient with a near obstructing villous adenoma found on colon cancer screening and Barrett's esophagus. J Cyst Fibros (2007) 0.90
Enthalpy-entropy compensation in dinitrophenyl--anti-dinitrophenyl antibody interaction(s). Immunology (1977) 0.90
Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-alpha release. Am J Physiol (1999) 0.90
Upper gastrointestinal toxicity of alendronate. Am J Gastroenterol (2000) 0.90
Attenuation of epithelial injury in acute experimental colitis by immunomodulators. Eur J Pharmacol (1993) 0.89
Synchronous collagenous sprue and enteropathy-type T cell lymphoma: variants of the same disease. Can J Gastroenterol (2004) 0.88